Therapeutic Resistance of Prostate Cancer Mediated by Cadherin T6
Abstract
In order to better understand the molecular basis for the development of therapeutic resistance by prostate cancer, we have undertaken experimentation in which we genetically compared therapy resistant prostate cancer cells to therapy sensitive prostate cancer cells. As a result of this comparison, we have identified a novel gene product, previously referred to as T6 (now referred to as Protocadherin-PC) that is highly upregulated when prostate cancer cells are selected for resistance to apoptotic agents in vitro and when these cells are selected for hormonal resistance in vivo. This progress report describes our success in characterizing the human Protocadherin-PC gene and gene product and in describing the probable mechanism through which this protein increases therapeutic resistance of prostate cancer cells. As a result of these studies, we believe that prostate cancer progresses to the state of therapeutic resistance in a mechanistically similar manner to that of human colon cancer and melanoma.
Document Details
- Document Type
- Technical Report
- Publication Date
- Oct 01, 1999
- Accession Number
- ADA383147
Entities
People
- Ralph Buttyan
Organizations
- Columbia University